ES2535412T3 - Vacuna para la profilaxis o el tratamiento de una patología de las vías respiratorias originada por un alérgeno - Google Patents

Vacuna para la profilaxis o el tratamiento de una patología de las vías respiratorias originada por un alérgeno

Info

Publication number
ES2535412T3
ES2535412T3 ES10715245.6T ES10715245T ES2535412T3 ES 2535412 T3 ES2535412 T3 ES 2535412T3 ES 10715245 T ES10715245 T ES 10715245T ES 2535412 T3 ES2535412 T3 ES 2535412T3
Authority
ES
Spain
Prior art keywords
pertussis
ova
allergen
live attenuated
bpze1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10715245.6T
Other languages
English (en)
Spanish (es)
Inventor
Camille Locht
Bernard Mahon
Heather Kavanagh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
National University of Ireland Maynooth
Original Assignee
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
National University of Ireland Maynooth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur, National University of Ireland Maynooth filed Critical Institut Pasteur de Lille
Application granted granted Critical
Publication of ES2535412T3 publication Critical patent/ES2535412T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES10715245.6T 2009-04-28 2010-04-26 Vacuna para la profilaxis o el tratamiento de una patología de las vías respiratorias originada por un alérgeno Active ES2535412T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305371 2009-04-28
EP09305371 2009-04-28
PCT/EP2010/055507 WO2010125014A1 (en) 2009-04-28 2010-04-26 Vaccine for prophylaxis or treatment of an allergen-driven airway pathology

Publications (1)

Publication Number Publication Date
ES2535412T3 true ES2535412T3 (es) 2015-05-11

Family

ID=41057387

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10715245.6T Active ES2535412T3 (es) 2009-04-28 2010-04-26 Vacuna para la profilaxis o el tratamiento de una patología de las vías respiratorias originada por un alérgeno
ES19176782T Active ES3024937T3 (en) 2009-04-28 2010-04-26 Vaccine for prophylaxis or treatment of an allergen-driven airway pathology

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES19176782T Active ES3024937T3 (en) 2009-04-28 2010-04-26 Vaccine for prophylaxis or treatment of an allergen-driven airway pathology

Country Status (10)

Country Link
US (7) US20120177688A1 (cg-RX-API-DMAC7.html)
EP (3) EP2910252A1 (cg-RX-API-DMAC7.html)
JP (1) JP5678034B2 (cg-RX-API-DMAC7.html)
CN (1) CN102448490B (cg-RX-API-DMAC7.html)
AU (1) AU2010243708C1 (cg-RX-API-DMAC7.html)
CA (1) CA2759280C (cg-RX-API-DMAC7.html)
DK (1) DK2424564T3 (cg-RX-API-DMAC7.html)
ES (2) ES2535412T3 (cg-RX-API-DMAC7.html)
SG (1) SG175803A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010125014A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2821830T3 (es) 2006-03-10 2021-04-27 Pasteur Institut Cepas de Bordetella vivas atenuadas como vacuna de dosis única contra la tos ferina
DK2424564T3 (en) 2009-04-28 2015-04-27 Inserm Inst Nat De La Santé Et De La Rech Médicale A vaccine for the prevention or treatment of a respiratory pathology allergendrevet
WO2010146414A1 (en) 2009-06-15 2010-12-23 National University Of Singapore Influenza vaccine, composition, and methods of use
EP2773371B1 (en) * 2011-11-02 2020-01-01 National University of Singapore Effect of an attenuated bordetella strain against allergic disease
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
US9757428B2 (en) 2013-08-16 2017-09-12 University Of Rochester Designed peptides for tight junction barrier modulation
US9655959B2 (en) * 2014-10-01 2017-05-23 National University Of Singapore Adenylate cyclase deficient bordetella strains
WO2017167834A1 (en) * 2016-03-29 2017-10-05 Institut Pasteur De Lille Mutant bordetella strains and methods for use
JP6598724B2 (ja) 2016-04-07 2019-10-30 株式会社ジェイテクト ステアリング装置
CN111278456B (zh) 2017-10-18 2024-08-09 里尔巴斯德研究所 表达血清3型菌毛的鲍特菌属菌株
WO2020247347A1 (en) 2019-06-05 2020-12-10 University Of Rochester New designed inhibitors of tight junction formation
US20250263447A1 (en) * 2020-09-04 2025-08-21 Intravacc B.V. Ompa mutations enhance omv production in bordetella pertussis
EP3909971A1 (en) 2020-09-28 2021-11-17 Institute of Life Sciences (ILS) Whole cell livestock vaccine for respiratory diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883761A (en) 1986-03-25 1989-11-28 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
US5101019A (en) * 1987-05-22 1992-03-31 Takeda Chemical Industries, Ltd. Method for removing pertussis endotoxin, a pertussis toxoid and its production
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
GB9115332D0 (en) 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
FR2754543B1 (fr) 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
FR2840319B1 (fr) * 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
AU2004229527B2 (en) * 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions
GB0402131D0 (en) 2004-01-30 2004-03-03 Isis Innovation Delivery method
ES2821830T3 (es) 2006-03-10 2021-04-27 Pasteur Institut Cepas de Bordetella vivas atenuadas como vacuna de dosis única contra la tos ferina
WO2008118592A2 (en) 2007-02-23 2008-10-02 The Penn State Research Foundation Use of an avirulent bordetella mutant as a live vaccine vector
CN100537767C (zh) * 2007-04-29 2009-09-09 中国药品生物制品检定所 百日咳疫苗保护性抗原的重组表达及其应用
DK2424564T3 (en) 2009-04-28 2015-04-27 Inserm Inst Nat De La Santé Et De La Rech Médicale A vaccine for the prevention or treatment of a respiratory pathology allergendrevet
CN101947323B (zh) * 2010-07-26 2013-02-27 北京绿竹生物制药有限公司 一种革兰氏阴性细菌疫苗及其制备方法
EP2773371B1 (en) 2011-11-02 2020-01-01 National University of Singapore Effect of an attenuated bordetella strain against allergic disease
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
US9655959B2 (en) 2014-10-01 2017-05-23 National University Of Singapore Adenylate cyclase deficient bordetella strains
WO2017167834A1 (en) 2016-03-29 2017-10-05 Institut Pasteur De Lille Mutant bordetella strains and methods for use
US10799573B2 (en) 2016-03-30 2020-10-13 Regents Of The University Of Minnesota Pertussis vaccines and methods of making and using
WO2018213361A1 (en) 2017-05-15 2018-11-22 Vanderbilt University LONG-CIRCULATING ZWITTERIONIC POLYPLEXES FOR siRNA DELIVERY
JP7404226B2 (ja) 2017-07-18 2023-12-25 セラム インスティテュート オブ インディア プライベート リミティド 向上した安定性、高度の免疫原性、及び減少した反応源性を有する免疫原性組成物、並びにその調製プロセス
CN111278456B (zh) 2017-10-18 2024-08-09 里尔巴斯德研究所 表达血清3型菌毛的鲍特菌属菌株
US12036405B2 (en) 2018-03-23 2024-07-16 The Board Of Regents Of The University Of Oklahoma System and method of electric-induced acoustic tomography for electrotherapy monitoring

Also Published As

Publication number Publication date
US20130183336A1 (en) 2013-07-18
EP2424564B1 (en) 2015-02-25
WO2010125014A1 (en) 2010-11-04
CA2759280C (en) 2016-09-20
AU2010243708B2 (en) 2014-06-12
CN102448490A (zh) 2012-05-09
US20120177688A1 (en) 2012-07-12
US10653765B2 (en) 2020-05-19
EP3590532C0 (en) 2025-03-19
DK2424564T3 (en) 2015-04-27
US9839683B2 (en) 2017-12-12
EP3590532B1 (en) 2025-03-19
AU2010243708A1 (en) 2011-11-03
US11110161B2 (en) 2021-09-07
US11819545B2 (en) 2023-11-21
US20210361759A1 (en) 2021-11-25
US8986709B2 (en) 2015-03-24
CN102448490B (zh) 2015-05-13
CA2759280A1 (en) 2010-11-04
US20200282041A1 (en) 2020-09-10
US20150182614A1 (en) 2015-07-02
SG175803A1 (en) 2011-12-29
JP2012525346A (ja) 2012-10-22
AU2010243708C1 (en) 2014-10-02
EP2424564A1 (en) 2012-03-07
US20190358309A1 (en) 2019-11-28
US10420827B2 (en) 2019-09-24
JP5678034B2 (ja) 2015-02-25
EP2910252A1 (en) 2015-08-26
ES3024937T3 (en) 2025-06-05
EP3590532A1 (en) 2020-01-08
US20180085450A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
ES2535412T3 (es) Vacuna para la profilaxis o el tratamiento de una patología de las vías respiratorias originada por un alérgeno
ES2753779T3 (es) Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes
ES2758679T3 (es) Composiciones que comprenden cepas bacterianas
ES2821830T3 (es) Cepas de Bordetella vivas atenuadas como vacuna de dosis única contra la tos ferina
ES2748826T3 (es) Composiciones que comprenden cepas bacterianas
ES2748812T3 (es) Composiciones que comprenden cepas bacterianas
Locht Will we have new pertussis vaccines?
Kavanagh et al. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen‐induced immunity and prevents allergic pulmonary pathology in a murine model
Chang et al. Nasal vaccination with GroEL plus CpG ODN inhibits P. Gingivalis-induced inflammation and alveolar bone loss
Mahon et al. Whole-cell pertussis vaccine protects against Bordetella pertussis exacerbation of allergic asthma
HK1226777B (en) Live attenuated bordetella strains as a single dose vaccine against whooping cough
HK1124090B (en) Live attenuated bordetella strains as a single dose vaccine against whooping cough
HK1262896B (zh) 突变型博德特氏菌属菌株及其使用方法